nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—Citalopram—ABCB1—adrenal gland cancer	0.987	1	CrCbGaD
Escitalopram—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—adrenal gland cancer	0.000161	0.0119	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.000152	0.0113	CbGpPWpGaD
Escitalopram—SLC6A4—SIDS Susceptibility Pathways—PRKACA—adrenal gland cancer	0.000147	0.0109	CbGpPWpGaD
Escitalopram—HTR2C—G alpha (q) signalling events—GNRH1—adrenal gland cancer	0.000138	0.0102	CbGpPWpGaD
Escitalopram—SLC6A4—Circadian rythm related genes—TOP2A—adrenal gland cancer	0.000136	0.0101	CbGpPWpGaD
Escitalopram—ADRA1A—G alpha (12/13) signalling events—CDC42—adrenal gland cancer	0.000132	0.00981	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.000132	0.0098	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.000132	0.00977	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.000129	0.00962	CbGpPWpGaD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—adrenal gland cancer	0.000123	0.00915	CbGpPWpGaD
Escitalopram—HRH1—IL-4 Signaling Pathway—BAD—adrenal gland cancer	0.000122	0.00907	CbGpPWpGaD
Escitalopram—HRH1—G alpha (q) signalling events—GNRH1—adrenal gland cancer	0.000119	0.00887	CbGpPWpGaD
Escitalopram—CHRM1—G alpha (q) signalling events—GNRH1—adrenal gland cancer	0.000119	0.00884	CbGpPWpGaD
Escitalopram—ADRA1A—G alpha (q) signalling events—GNRH1—adrenal gland cancer	0.000117	0.0087	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—GNRHR—adrenal gland cancer	0.000116	0.00862	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—adrenal gland cancer	0.000107	0.00793	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—adrenal gland cancer	0.000106	0.00791	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—adrenal gland cancer	0.000105	0.00778	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—GNRHR—adrenal gland cancer	0.0001	0.00747	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—GNRHR—adrenal gland cancer	0.0001	0.00744	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—GNRHR—adrenal gland cancer	9.86e-05	0.00733	CbGpPWpGaD
Escitalopram—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—adrenal gland cancer	9.68e-05	0.0072	CbGpPWpGaD
Escitalopram—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—adrenal gland cancer	9.23e-05	0.00685	CbGpPWpGaD
Escitalopram—SLC6A3—Transmission across Chemical Synapses—PRKACA—adrenal gland cancer	9.18e-05	0.00682	CbGpPWpGaD
Escitalopram—CHRM1—Calcium Regulation in the Cardiac Cell—PRKACA—adrenal gland cancer	9.13e-05	0.00678	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	9.12e-05	0.00678	CbGpPWpGaD
Escitalopram—ADRA1A—Calcium Regulation in the Cardiac Cell—PRKACA—adrenal gland cancer	8.99e-05	0.00668	CbGpPWpGaD
Escitalopram—CHRM1—Circadian rythm related genes—TOP2A—adrenal gland cancer	8.16e-05	0.00606	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	8.13e-05	0.00604	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	7.91e-05	0.00587	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	7.88e-05	0.00585	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	7.76e-05	0.00576	CbGpPWpGaD
Escitalopram—CHRM1—Regulation of Actin Cytoskeleton—CDC42—adrenal gland cancer	7.74e-05	0.00575	CbGpPWpGaD
Escitalopram—CHRM1—Calcium Regulation in the Cardiac Cell—GNAS—adrenal gland cancer	7.4e-05	0.0055	CbGpPWpGaD
Escitalopram—ADRA1A—Calcium Regulation in the Cardiac Cell—GNAS—adrenal gland cancer	7.28e-05	0.00541	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	7.05e-05	0.00524	CbGpPWpGaD
Escitalopram—SLC6A3—Neuronal System—PRKACA—adrenal gland cancer	7.03e-05	0.00522	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	7.02e-05	0.00522	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—GNRH1—adrenal gland cancer	6.95e-05	0.00516	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	6.91e-05	0.00514	CbGpPWpGaD
Escitalopram—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	6.68e-05	0.00497	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—GNRHR—adrenal gland cancer	6.55e-05	0.00487	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—TSHR—adrenal gland cancer	6.19e-05	0.0046	CbGpPWpGaD
Escitalopram—CYP2C19—Arachidonic acid metabolism—PTGS2—adrenal gland cancer	6.17e-05	0.00458	CbGpPWpGaD
Escitalopram—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	6.15e-05	0.00457	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—GNRH1—adrenal gland cancer	6.02e-05	0.00447	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—GNRH1—adrenal gland cancer	6e-05	0.00446	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—GNRHR—adrenal gland cancer	5.95e-05	0.00442	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—GNRH1—adrenal gland cancer	5.91e-05	0.00439	CbGpPWpGaD
Escitalopram—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—adrenal gland cancer	5.72e-05	0.00425	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—GNRHR—adrenal gland cancer	5.68e-05	0.00422	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—GNRHR—adrenal gland cancer	5.66e-05	0.00421	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—GNRHR—adrenal gland cancer	5.57e-05	0.00414	CbGpPWpGaD
Escitalopram—CYP2C19—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	5.42e-05	0.00403	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—TSHR—adrenal gland cancer	5.37e-05	0.00399	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—TSHR—adrenal gland cancer	5.35e-05	0.00397	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—TSHR—adrenal gland cancer	5.27e-05	0.00391	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—GNRHR—adrenal gland cancer	5.16e-05	0.00383	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—GNRHR—adrenal gland cancer	5.14e-05	0.00382	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—GNRHR—adrenal gland cancer	5.06e-05	0.00376	CbGpPWpGaD
Escitalopram—CYP2D6—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	4.98e-05	0.0037	CbGpPWpGaD
Escitalopram—SLC6A3—Transmission across Chemical Synapses—BRAF—adrenal gland cancer	4.95e-05	0.00367	CbGpPWpGaD
Escitalopram—CHRM1—Regulation of Actin Cytoskeleton—BRAF—adrenal gland cancer	4.92e-05	0.00365	CbGpPWpGaD
Escitalopram—ADRA1A—AMPK Signaling—TP53—adrenal gland cancer	4.31e-05	0.0032	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—PRKACA—adrenal gland cancer	4.27e-05	0.00317	CbGpPWpGaD
Escitalopram—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	4.02e-05	0.00299	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—GNRH1—adrenal gland cancer	3.93e-05	0.00292	CbGpPWpGaD
Escitalopram—SLC6A3—Neuronal System—BRAF—adrenal gland cancer	3.79e-05	0.00282	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—PRKACA—adrenal gland cancer	3.78e-05	0.00281	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—GNAS—adrenal gland cancer	3.6e-05	0.00268	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—GNRH1—adrenal gland cancer	3.57e-05	0.00265	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—GNRHR—adrenal gland cancer	3.52e-05	0.00261	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—TSHR—adrenal gland cancer	3.5e-05	0.0026	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	3.46e-05	0.00257	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—GNRH1—adrenal gland cancer	3.4e-05	0.00253	CbGpPWpGaD
Escitalopram—SLC6A2—Transmembrane transport of small molecules—ABCB1—adrenal gland cancer	3.39e-05	0.00252	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—GNRH1—adrenal gland cancer	3.39e-05	0.00252	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—GNRH1—adrenal gland cancer	3.34e-05	0.00248	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—SH3KBP1—adrenal gland cancer	3.27e-05	0.00243	CbGpPWpGaD
Escitalopram—CYP3A4—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	3.26e-05	0.00242	CbGpPWpGaD
Escitalopram—HTR2C—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	3.19e-05	0.00237	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—TSHR—adrenal gland cancer	3.18e-05	0.00236	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—GNAS—adrenal gland cancer	3.12e-05	0.00232	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—GNAS—adrenal gland cancer	3.11e-05	0.00231	CbGpPWpGaD
Escitalopram—SLC6A4—Circadian rythm related genes—TP53—adrenal gland cancer	3.11e-05	0.00231	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—GNRH1—adrenal gland cancer	3.09e-05	0.0023	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—GNRH1—adrenal gland cancer	3.08e-05	0.00229	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ZNRF3—adrenal gland cancer	3.07e-05	0.00228	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	3.06e-05	0.00228	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—GNAS—adrenal gland cancer	3.06e-05	0.00228	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—GNRHR—adrenal gland cancer	3.05e-05	0.00226	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—GNRHR—adrenal gland cancer	3.04e-05	0.00226	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—TSHR—adrenal gland cancer	3.03e-05	0.00225	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—GNRH1—adrenal gland cancer	3.03e-05	0.00225	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—TSHR—adrenal gland cancer	3.02e-05	0.00225	CbGpPWpGaD
Escitalopram—SLC6A3—Transmembrane transport of small molecules—ABCB1—adrenal gland cancer	3.01e-05	0.00223	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—GNRHR—adrenal gland cancer	2.99e-05	0.00222	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—TSHR—adrenal gland cancer	2.98e-05	0.00221	CbGpPWpGaD
Escitalopram—CYP2C19—Biological oxidations—POMC—adrenal gland cancer	2.88e-05	0.00214	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—SH3KBP1—adrenal gland cancer	2.83e-05	0.0021	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—SH3KBP1—adrenal gland cancer	2.82e-05	0.0021	CbGpPWpGaD
Escitalopram—CHRM1—Regulation of Actin Cytoskeleton—EGFR—adrenal gland cancer	2.82e-05	0.00209	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—SH3KBP1—adrenal gland cancer	2.78e-05	0.00206	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	2.78e-05	0.00206	CbGpPWpGaD
Escitalopram—HRH1—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	2.76e-05	0.00205	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—TSHR—adrenal gland cancer	2.75e-05	0.00205	CbGpPWpGaD
Escitalopram—CHRM1—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	2.75e-05	0.00204	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—TSHR—adrenal gland cancer	2.74e-05	0.00204	CbGpPWpGaD
Escitalopram—ADRA1A—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	2.71e-05	0.00201	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—TSHR—adrenal gland cancer	2.7e-05	0.00201	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ZNRF3—adrenal gland cancer	2.66e-05	0.00198	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ZNRF3—adrenal gland cancer	2.65e-05	0.00197	CbGpPWpGaD
Escitalopram—CYP2D6—Biological oxidations—POMC—adrenal gland cancer	2.65e-05	0.00197	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ZNRF3—adrenal gland cancer	2.61e-05	0.00194	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—SDHB—adrenal gland cancer	2.57e-05	0.00191	CbGpPWpGaD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	2.43e-05	0.00181	CbGpPWpGaD
Escitalopram—HTR2C—GPCR ligand binding—POMC—adrenal gland cancer	2.43e-05	0.0018	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SDHB—adrenal gland cancer	2.37e-05	0.00176	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—PRKACA—adrenal gland cancer	2.28e-05	0.00169	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—CDC42—adrenal gland cancer	2.13e-05	0.00158	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	2.11e-05	0.00157	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—GNRH1—adrenal gland cancer	2.11e-05	0.00156	CbGpPWpGaD
Escitalopram—HRH1—GPCR ligand binding—POMC—adrenal gland cancer	2.1e-05	0.00156	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	2.1e-05	0.00156	CbGpPWpGaD
Escitalopram—CHRM1—GPCR ligand binding—POMC—adrenal gland cancer	2.09e-05	0.00156	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	2.07e-05	0.00154	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR ligand binding—POMC—adrenal gland cancer	2.06e-05	0.00153	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—GNAS—adrenal gland cancer	2.04e-05	0.00151	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	2.03e-05	0.0015	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PRKACA—adrenal gland cancer	1.98e-05	0.00147	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PRKACA—adrenal gland cancer	1.97e-05	0.00146	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PRKACA—adrenal gland cancer	1.94e-05	0.00144	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—CDC42—adrenal gland cancer	1.93e-05	0.00144	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—SPRY2—adrenal gland cancer	1.93e-05	0.00143	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TSHR—adrenal gland cancer	1.88e-05	0.00139	CbGpPWpGaD
Escitalopram—CHRM1—Circadian rythm related genes—TP53—adrenal gland cancer	1.86e-05	0.00138	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—GNAS—adrenal gland cancer	1.85e-05	0.00137	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—CDC42—adrenal gland cancer	1.85e-05	0.00137	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—CDC42—adrenal gland cancer	1.84e-05	0.00137	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—GNRH1—adrenal gland cancer	1.83e-05	0.00136	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—GNRH1—adrenal gland cancer	1.82e-05	0.00135	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—CDC42—adrenal gland cancer	1.81e-05	0.00135	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—GNRH1—adrenal gland cancer	1.79e-05	0.00133	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MEN1—adrenal gland cancer	1.77e-05	0.00131	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—GNAS—adrenal gland cancer	1.76e-05	0.00131	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—GNAS—adrenal gland cancer	1.76e-05	0.00131	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—GNAS—adrenal gland cancer	1.73e-05	0.00129	CbGpPWpGaD
Escitalopram—CYP3A4—Biological oxidations—POMC—adrenal gland cancer	1.73e-05	0.00129	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—CDC42—adrenal gland cancer	1.68e-05	0.00125	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—CDC42—adrenal gland cancer	1.67e-05	0.00124	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—SPRY2—adrenal gland cancer	1.67e-05	0.00124	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—SPRY2—adrenal gland cancer	1.66e-05	0.00124	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—RRM1—adrenal gland cancer	1.66e-05	0.00123	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—SDHD—adrenal gland cancer	1.66e-05	0.00123	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—CDC42—adrenal gland cancer	1.65e-05	0.00122	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—SPRY2—adrenal gland cancer	1.64e-05	0.00122	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TSHR—adrenal gland cancer	1.63e-05	0.00121	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TSHR—adrenal gland cancer	1.62e-05	0.0012	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—GNAS—adrenal gland cancer	1.6e-05	0.00119	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—GNAS—adrenal gland cancer	1.6e-05	0.00119	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TSHR—adrenal gland cancer	1.6e-05	0.00119	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—GNAS—adrenal gland cancer	1.57e-05	0.00117	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SDHB—adrenal gland cancer	1.55e-05	0.00115	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MEN1—adrenal gland cancer	1.53e-05	0.00114	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SDHD—adrenal gland cancer	1.53e-05	0.00113	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—RRM1—adrenal gland cancer	1.53e-05	0.00113	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MEN1—adrenal gland cancer	1.52e-05	0.00113	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MEN1—adrenal gland cancer	1.5e-05	0.00112	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—POMC—adrenal gland cancer	1.37e-05	0.00102	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PRKACA—adrenal gland cancer	1.35e-05	0.001	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—POMC—adrenal gland cancer	1.24e-05	0.000925	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—MED12—adrenal gland cancer	1.24e-05	0.000918	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—POMC—adrenal gland cancer	1.19e-05	0.000882	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—POMC—adrenal gland cancer	1.18e-05	0.00088	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PRKACA—adrenal gland cancer	1.17e-05	0.000867	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—POMC—adrenal gland cancer	1.17e-05	0.000866	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PRKACA—adrenal gland cancer	1.16e-05	0.000865	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PRKACA—adrenal gland cancer	1.15e-05	0.000851	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CDC42—adrenal gland cancer	1.14e-05	0.000849	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—MED12—adrenal gland cancer	1.14e-05	0.000845	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	1.11e-05	0.000821	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IGF2—adrenal gland cancer	1.1e-05	0.000818	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—GNAS—adrenal gland cancer	1.09e-05	0.000811	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—POMC—adrenal gland cancer	1.08e-05	0.000801	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—POMC—adrenal gland cancer	1.08e-05	0.000799	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IGF1R—adrenal gland cancer	1.07e-05	0.000791	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—POMC—adrenal gland cancer	1.06e-05	0.000786	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—RRM1—adrenal gland cancer	9.97e-06	0.000741	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SDHD—adrenal gland cancer	9.97e-06	0.000741	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CDC42—adrenal gland cancer	9.9e-06	0.000736	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CDC42—adrenal gland cancer	9.87e-06	0.000733	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CDC42—adrenal gland cancer	9.72e-06	0.000722	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IGF2—adrenal gland cancer	9.55e-06	0.000709	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IGF2—adrenal gland cancer	9.51e-06	0.000707	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—GNAS—adrenal gland cancer	9.46e-06	0.000703	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—GNAS—adrenal gland cancer	9.43e-06	0.000701	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IGF2—adrenal gland cancer	9.37e-06	0.000696	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—GNAS—adrenal gland cancer	9.29e-06	0.00069	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IGF1R—adrenal gland cancer	9.23e-06	0.000686	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IGF1R—adrenal gland cancer	9.2e-06	0.000683	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TERT—adrenal gland cancer	9.17e-06	0.000681	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IGF1R—adrenal gland cancer	9.06e-06	0.000673	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PRKACA—adrenal gland cancer	9.02e-06	0.00067	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	8.82e-06	0.000655	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PRKACA—adrenal gland cancer	8.3e-06	0.000616	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—BAD—adrenal gland cancer	7.98e-06	0.000593	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TERT—adrenal gland cancer	7.94e-06	0.00059	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TERT—adrenal gland cancer	7.92e-06	0.000588	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TERT—adrenal gland cancer	7.8e-06	0.000579	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—MED12—adrenal gland cancer	7.43e-06	0.000552	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—POMC—adrenal gland cancer	7.35e-06	0.000546	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GNAS—adrenal gland cancer	7.31e-06	0.000543	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—BRAF—adrenal gland cancer	7.26e-06	0.000539	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ABCB1—adrenal gland cancer	7.17e-06	0.000533	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—EGFR—adrenal gland cancer	7.04e-06	0.000523	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—BAD—adrenal gland cancer	6.91e-06	0.000513	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—BAD—adrenal gland cancer	6.89e-06	0.000512	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—BAD—adrenal gland cancer	6.78e-06	0.000504	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GNAS—adrenal gland cancer	6.72e-06	0.000499	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ABCB1—adrenal gland cancer	6.6e-06	0.00049	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—POMC—adrenal gland cancer	6.37e-06	0.000473	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—POMC—adrenal gland cancer	6.35e-06	0.000472	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—BRAF—adrenal gland cancer	6.29e-06	0.000467	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—BRAF—adrenal gland cancer	6.27e-06	0.000466	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—POMC—adrenal gland cancer	6.25e-06	0.000464	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—BRAF—adrenal gland cancer	6.17e-06	0.000459	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—EGFR—adrenal gland cancer	6.1e-06	0.000453	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—EGFR—adrenal gland cancer	6.08e-06	0.000452	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—EGFR—adrenal gland cancer	5.98e-06	0.000445	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	5.42e-06	0.000403	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CTNNB1—adrenal gland cancer	5.25e-06	0.00039	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—POMC—adrenal gland cancer	4.92e-06	0.000366	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CTNNB1—adrenal gland cancer	4.55e-06	0.000338	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CTNNB1—adrenal gland cancer	4.53e-06	0.000337	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—POMC—adrenal gland cancer	4.53e-06	0.000336	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CTNNB1—adrenal gland cancer	4.46e-06	0.000331	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GNAS—adrenal gland cancer	4.4e-06	0.000327	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	4.31e-06	0.00032	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—EGFR—adrenal gland cancer	4.16e-06	0.000309	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTGS2—adrenal gland cancer	3.93e-06	0.000292	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTGS2—adrenal gland cancer	3.61e-06	0.000268	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EGFR—adrenal gland cancer	3.6e-06	0.000268	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EGFR—adrenal gland cancer	3.59e-06	0.000267	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EGFR—adrenal gland cancer	3.53e-06	0.000263	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TP53—adrenal gland cancer	3.49e-06	0.000259	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TP53—adrenal gland cancer	3.02e-06	0.000225	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TP53—adrenal gland cancer	3.01e-06	0.000224	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TP53—adrenal gland cancer	2.97e-06	0.000221	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—POMC—adrenal gland cancer	2.96e-06	0.00022	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	2.36e-06	0.000175	CbGpPWpGaD
